Royce & Associates LP Increases Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Royce & Associates LP boosted its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 0.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,451,450 shares of the medical instruments supplier’s stock after buying an additional 10,000 shares during the period. Royce & Associates LP’s holdings in Harvard Bioscience were worth $3,904,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in Harvard Bioscience by 38.7% during the 1st quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after purchasing an additional 21,183 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after purchasing an additional 49,576 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new stake in shares of Harvard Bioscience during the first quarter valued at $112,000. Price T Rowe Associates Inc. MD bought a new position in shares of Harvard Bioscience in the first quarter worth about $54,000. Finally, Assenagon Asset Management S.A. increased its stake in Harvard Bioscience by 193.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock worth $649,000 after buying an additional 150,218 shares during the period. 80.87% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Trading Up 0.5 %

Shares of HBIO opened at $2.15 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.94. The firm has a market capitalization of $93.78 million, a price-to-earnings ratio of -6.67 and a beta of 1.31. The company has a 50-day moving average of $2.52 and a 200 day moving average of $2.89. Harvard Bioscience, Inc. has a 1-year low of $2.12 and a 1-year high of $5.56.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.